Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease

Hyo Min Park, MD1, Dong Won Lee, MD2, Myung Chul Hyun, MD, PhD1, Sang Bum Lee, MD, PhD1

1Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, 2Department of Pediatrics, Daegu Fatima Hospital, Daegu, Korea

Purpose: It has been reported that 10% to 20% of children with Kawasaki disease (KD) will not respond to intravenous immunoglobulin (IVIG) treatment. In this study, we aimed to identify useful predictors of therapeutic failure in children with KD.

Methods: We examined 309 children diagnosed with KD at the Kyungpook National University Hospital and the Inje University Busan Paik Hospital between January 2005 and June 2011. We retrospectively reviewed their medical records and analyzed multiple parameters in responders and nonresponders to IVIG.

Results: Among the 309 children, 30 (9.7%) did not respond to IVIG. They had significantly higher proportion of neutrophils, and higher levels of aspartate aminotransferase, alanine aminotransferase (ALT), total bilirubin, and N-terminal fragment of B-type natriuretic peptide than did responders. IVIG-nonresponders had a significantly longer duration of hospitalization, and more frequently experienced coronary artery lesion, and sterile pyuria. No differences in the duration of fever at initial treatment or, clinical features were noted.

Conclusion: Two independent predictors (ALT ≥ 84 IU/L, total bilirubin ≥ 0.9 mg/dL) for nonresponse were confirmed through multivariate logistic regression analysis. Thus elevated ALT and total bilirubin levels might be useful in predicting nonresponse to IVIG therapy in children with KD.

Key words: Kawasaki disease, Intravenous immunoglobulin, Predictor, Alanine aminotransferase, Total bilirubin

Introduction

Kawasaki disease (KD) is systemic vasculitis that can cause coronary artery complications, and is the most common cause of pediatric acquired cardiac disease in developed countries. Some cases are recovered naturally without treatment, but around 15% to 25% have complications such as coronary aneurysm and coronary artery ectasia. Such complications may develop into cardiac infarction, sudden death or ischemic heart disease1,2). The use of high-dose intravenous immunoglobulin (IVIG) and aspirin lowered the frequency of coronary artery complications caused by KD to below 5%, and its morbidity and mortality also went down3). Though its mechanism of action is not clear, immunoglobulin has a systemic anti-inflammatory action, modulating the production of cytokine, neutralizing bacterial superantigen or other etiologic agents, amplifying T-cell suppressor activity, and inhibiting the production of antibody2,3).

However, 10% to 20% of KD patients do not respond to the conventional therapy and have continued fever, and such cases are in need of a different rescue therapy4,5). In the patient group not responding to IVIG and aspirin, the risk of coronary artery complications is very high. For these problems, many studies have been conducted for the early
identification of patients who do not respond to IVIG. Many reports have been made particularly in Japan, and they reported involved factors such as pediatric patients’ age, duration between the onset of fever and the administration of IVIG, sodium level, proportion of neutrophil, C-reactive protein (CRP), platelet count, albumin, total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), and developed risk-scoring systems using several factors. Nevertheless, there are no agreed factors for predicting patients not responding to IVIG.

Thus, the present authors conducted this study in order to find clinical patterns and laboratory findings important for predicting patients not responding to IVIG.

Materials and methods

1. Patients

The subjects of this study were 309 patients diagnosed with KD and treated at the Kyungpook National University Hospital and the Inje University Busan Paik Hospital during the period from January 2005 to June 2011. KD was diagnosed according to the criteria published by American Heart Association in 2004. For all the patients, we collected samples on the day of admission or before immunoglobulin treatment, and measured hemoglobin (Hb), white blood cell, proportion of neutrophil, platelet count, erythrocyte sedimentation rate, CRP, AST, ALT, sodium, potassium, total protein, albumin, total bilirubin, total cholesterol, triglyceride, high density lipoprotein (HDL), and N-terminal fragment of B-type natriuretic peptide (NT-proBNP).

All of the patients were administered with IVIG (2 g/kg) and high-dose aspirin (80–100 mg/kg/day). Those who showed improvement in fever and other symptoms after the administration of IVIG were classified as IVIG-responders, and those whose fever continued for over 36 hours or who had recrudescence fever (temperature≥38.0 °C axillary or rectal) were classified as IVIG-nonresponders. In addition, echocardiography was performed to measure coronary artery size at diagnosis. Coronary artery lesion was defined as follows; 1) coronary artery diameter had a Z-score≥2.5, 2) size of coronary artery had 1.5 times larger than other lesions.

2. Risk-scoring systems

The parameters of Kobayashi score are as follows: 1) sodium ≤133 mmol/L, 2 points; 2) days of illness at initial treatment ≤4 days, 2 points; 3) AST ≥100 IU/L, 2 points; 4) % of neutrophil≥80, 2 points; 5) CRP≥10 mg/dL, 1 point; 6) age≤12 months, 1 point; and 7) platelet count≤300×10⁹/mm³, 1 point. The parameters of Egami score are as follows: 1) ALT≥80 IU/L, 2 points; 2) illness days≤4 days, 1 point; 3) CRP≥8 mg/dL, 1 point; 4) ages 6 months, 1 point; and 5) platelet count≤300×10⁹/mm³, 1 point. The Sano scoring system is as follows: 1) AST≥200 IU/L, 1 point; 2) CRP≥7 mg/dL, 1 point; and 3) total bilirubin≥0.9 mg/dL, 1 point.

By applying each scoring system to our data, we divided the subjects into low-risk and high-risk groups and obtained sensitivity and specificity.

3. Statistical analysis

The groups were compared through Mann–Whitney U-test and Student’s t-test. And comparison according to age, weight and gender and the comparison of the frequency of coronary artery lesion were made through chi-square test using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). We determined significant parameters by univariate analyses, and then the cutoff values of these factors were obtained using receiver operating characteristic (ROC) curve. With these factors in addition to age (not older than 12 months), the duration of fever at the beginning of treatment (not longer than 4 days) and gender (male), which are factors suggested as the predictors of IVIG-resistant KD suggested in the previous reports, we performed multivariable logistic regression analysis. In all analyses, the statistical significance of difference was accepted if P<0.05.

4. Ethics statement

The study protocol was reviewed and approved by the Institutional Review Board (IRB) of the Inje University Busan Paik Hospital (IRB No. 12-053).

Results

1. Comparison of clinical findings between groups

Among the 309 patients, 30 (9.7%) did not respond to IVIG. Between the IVIG-responders and IVIG-nonresponders, no difference was observed in age, gender, and the duration of fever on diagnosis (P=0.987, P=0.195, and P=0.737). The clinical pattern of KD was not different between the two groups, but the frequency of sterile pyuria was higher in the IVIG-nonresponders (19/30, 63.3%) than in the IVIG-responders (67/279, 24.0%), and hospitalization time was also around two times longer in the IVIG-nonresponders (P<0.001). The frequency of coronary artery lesion was 43.3% (13/30) in the IVIG-nonresponders, more frequent than 6.8% (19/279) in the IVIG-responders (P<0.001) (Table 1).

Of the 30 IVIG-nonresponders, 22 were retreated with IVIG (2 g/kg). Six did not respond to IVIG-retreatment were given pulse methylprednisolone (30 mg/kg dose for 3 days), and 2 who did not respond to IVIG and steroid was treated with infliximab (5
2. Comparison of biological markers and risk-scoring systems between groups

AST, ALT, total bilirubin, % neutrophils, and NT-proBNP were significantly higher in the IVIG-responders than in the IVIG-nonresponders, and sodium level and HDL level were lower in the IVIG-nonresponders than in the IVIG-responders. Previously reported risk factors such as CRP, platelet count, and albumin were not significantly different in this study (Table 2). When data on our patients was applied to Kobayashi score, Sano score, and which are risk-scoring systems for predicting IVIG-resistant KD, were significantly higher in the IVIG-nonresponder group. The sensitivity and specificity of the Kobayashi model was 60% and 74%, respectively, and those of the Egami model were 57% and 77%, respectively. The Sano model showed sensitivity of 60% and specificity of 90% (Table 3).

3. Cutoff values of biomarkers by ROC curve

For each biomarker, the cutoff value was decided by the ROC curve. When the cutoff value of % neutrophils for identifying IVIG-nonresponders was set to 76%, the area under the ROC curve was 0.689 (95% confidence interval [CI], 0.580 to 0.798), sensitivity was 63%, and specificity was 74%. When the cutoff value of AST was 56 IU/dL, the area under the ROC curve was 0.683 (95% CI, 0.564 to 0.801), sensitivity was 60%, and specificity was 71%. For ALT, at cutoff value of 84 IU/dL, the area under the ROC curve was 0.751 (95% CI, 0.654 to 0.847), sensitivity was 73%, and specificity was 75%. At cutoff value of 0.9 mg/dL of total bilirubin, the area under the ROC curve was 0.739 (95% CI, 0.627 to 0.852), sensitivity was 70%, and specificity was 86%. At cutoff value 136 mmol/L of sodium level, the area under the ROC curve was 0.706 (95% CI, 0.626 to 0.786), sensitivity was 70%, and specificity was 59%.

4. Independent predictors of IVIG-nonresponders

According to the results of multivariable logistic regression analysis, the independent risk factors of IVIG-nonresponders were ALT≥84 IU/dL and total bilirubin≥0.9 mg/dL. The odds ratio was 3.8 for ALT, and 5.3 for total bilirubin. Having both of the two predictors (ALT≥84 IU/dL, total bilirubin≥0.9 mg/dL) in laboratory findings showed higher sensitivity and specificity (63% and 90%, respectively) than the existing models in predicting KD patients not responding to initial IVIG (Table 4).

Table 1. Characteristics of patients between IVIG-responders and IVIG-nonresponders

| Characteristic          | IVIG-responders (n=279) | IVIG-nonresponders (n=30) | P value |
|------------------------|-------------------------|---------------------------|---------|
| Age (mo)               | 26.0 (13–44)            | 27.5 (16.8–38.3)          | 0.987   |
| Male                   | 142 (50.9)              | 19 (63.3)                 | 0.195   |
| Duration of fever (day)| 5 (4–6)                 | 5 (4–6)                   | 0.737   |
| Hospitalization time (day) | 6 (5–7)             | 11 (9–14)                 | <0.001  |
| Sterile pyuria         | 67 (24.0)               | 19 (63.3)                 | <0.001  |
| CAL                    | 19 (6.8)                | 13 (43.3)                 | <0.001  |

Values are presented as median (25th to 75th percentiles) or number (%).

IVIG, intravenous immunoglobulin; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high density lipoprotein.

Table 2. Comparison of biological markers between IVIG-responders and IVIG-nonresponders

| Variable              | IVIG-responders (n=279) | IVIG-nonresponders (n=30) | P value |
|-----------------------|-------------------------|---------------------------|---------|
| Hemoglobin (g/dL)     | 11.6±1.1                | 11.4±1.2                  | 0.366   |
| WBC (×10^3/mm³)       | 13.7±5.1                | 14.7±6.0                  | 0.318   |
| % of neutrophils      | 64.5±15.7               | 74.2±15.7                 | 0.001   |
| Platelet (×10^3/mm³)  | 398.0±141.7             | 348.0±143.4               | 0.307   |
| ESR (mm/hr)           | 54.1±26.3               | 60.2±27.0                 | 0.227   |
| CRP (mg/dL)           | 7.3±8.0                 | 9.1±5.0                   | 0.200   |
| AST (IU/L)            | 64.2±101.5              | 125.8±118.0               | 0.009   |
| ALT (IU/L)            | 81.7±122.8              | 164.0±110.5               | <0.001  |
| Sodium (mmol/L)       | 137.2±3.5               | 134.7±2.9                 | <0.001  |
| Potassium (mmol/L)    | 4.5±2.4                 | 4.3±0.5                   | 0.599   |
| Total protein (g/dL)  | 6.8±0.6                 | 6.7±0.9                   | 0.686   |
| Albumin (g/dL)        | 4.0±2.0                 | 3.5±0.5                   | 0.226   |
| Total bilirubin (mg/dL)| 0.7±1.1               | 1.8±1.5                   | 0.001   |
| Total cholesterol (mg/dL)| 136.5±27.3         | 130.0±31.4                 | 0.265   |
| Triglyceride (mg/dL)  | 106.9±43.8              | 134.6±70.5                | 0.065   |
| HDL (mg/dL)           | 33.8±12.3               | 24.7±14.3                 | 0.001   |
| NT-proBNP (pg/mL)     | 920.6±1067.3            | 1,787.5±1629.8            | 0.017   |

Values are presented as mean±standard deviation.

IVIG, intravenous immunoglobulin; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high density lipoprotein.

Table 3. Comparison between IVIG-responders and IVIG-nonresponders applied to risk-scoring systems

| Variable              | IVIG-responders (n=279) | IVIG-nonresponders (n=30) | P value |
|-----------------------|-------------------------|---------------------------|---------|
| Kobayashi score*      | 2.4±1.9                 | 4.4±2.3                   | <0.001  |
| Low risk (0–3)        | 206 (74)                | 12 (40)                   |         |
| High risk (≥4)        | 73 (26)                 | 18 (60)                   |         |
| Egami score†          | 1.6±1.2                 | 2.6±1.3                   | <0.001  |
| Low risk (0–2)        | 214 (77)                | 13 (43)                   |         |
| High risk (≥3)        | 65 (23)                 | 17 (57)                   |         |
| Sano score‡           | 1.1±0.6                 | 1.8±0.6                   | <0.001  |
| Low risk (0–1)        | 252 (90)                | 12 (40)                   |         |
| High risk (≥2)        | 27 (10)                 | 18 (60)                   |         |

Values are presented as mean±standard deviation or number (%).

*Scores calculated by Kobayashi predictive system. †Scores by Egami system. ‡Scores by Sano system.
### Table 4. Multivariate analysis of IVIG-nonresponders

| Risk factor                      | Odds ratio (95% CI) | P value |
|----------------------------------|---------------------|---------|
| Age (≤12 mo)                     | 0.986 (0.301–3.228) | 0.982   |
| Illness at initial treatment (≤4 days) | 0.924 (0.363–2.352) | 0.868   |
| Gender (male)                    | 1.937 (0.790–4.748) | 0.148   |
| Neutrophil (>76%)                | 1.945 (0.693–5.459) | 0.206   |
| Sodium (≤136 mmol/L)             | 0.657 (0.253–1.709) | 0.389   |
| AST (≥56 IU/L)                   | 0.546 (0.172–1.730) | 0.304   |
| ALT (≥84 IU/L)                   | 3.780 (1.132–12.616) | 0.031   |
| Total bilirubin (≥0.9 mg/dL)     | 5.330 (1.721–16.505) | 0.004   |
| Sterile pyuria                   | 1.714 (0.634–4.633) | 0.288   |

IVG, intravenous immunoglobulin; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

### Discussion

From the results of this study, we found two predictors (ALT ≥ 84 IU/dL and total bilirubin ≥ 0.9 mg/dL) for KD not responding to initial IVIG treatment. In addition, the frequency of coronary artery lesion was much higher in IVIG-resistant KD, and pulse methylprednisolone and anti-tumor necrosis factor (TNF)-α monoclonal antibody (infliximab) were found to be useful and effective as rescue therapy.

Research is being made actively for reducing the duration of fever and coronary artery lesions through early detection and treatment of patients not responding to IVIG, who occupy around 10% to 20% of KD. Still, no agreed risk factors have been found. Many of studies on such risk factors were conducted with Japanese patients, and Kobayashi et al., Sano et al., Egami et al., etc. proposed scoring system for predicting IVIG-nonresponders using various parameters. When these risk-scoring systems were applied to the subjects of our study, specificity was high (74% to 90%) but sensitivity was low (57% to 60%), so they had difficulty in screening out high-risk patients who need intensive treatment. After all, there is a problem in applying the risk-scoring systems, which are effective to Japanese pediatric patients, to Korean pediatric patients due to difference in genetic factors between Japanese and Korean patients.

In other studies, Ashouri et al. reported risk predictors such as high percent band count, low albumin and the presence of coronary artery lesions. Tremoulet et al. mentioned high percent band count, long illness day, high gamma-glutamyl transferase, and low age-adjusted Hb as the risk predictors of IVIG-nonresponders. In Korea as well, Do et al. reported that low albumin, low sodium, and high neutrophil proportion were significant in the IVIG-resistant group. Changes in these biomarkers are the effects of diverse cytokines (interleukin [IL]-1β, TNF-α, interferon [IFN]-γ, IFN-α, IL-4, IL-6, IL-8, IL-10, transforming growth factor-β, matrix metalloproteinase, vascular endothelial growth factor (VEGF) increasing at the early stage). The elevation of VEGF induces the increase of vascular leakage, which in turn, decreases albumin. Furthermore, cytokine-activated natural killer cells accumulate in vascular endothelium and along liver sinusoids. As a result, inflammation of hepatic reticuloendothelial system and biliary tract occurs, that increases liver enzyme and total bilirubin. The accurate pathogenesis of hyponatremia in KD is unknown but is explained by the inappropriate secretion of antiuretic hormone caused by cerebral vasculitis and the direct renal loss of sodium resulting from the renal involvement of KD.

As in the previous studies, there were statistical differences in sodium level, liver enzymes (AST, ALT), total bilirubin, and neutrophil proportion in our study. The other parameters mentioned above were not significantly different. Moreover, high frequency of sterile pyuria, low HDL were observed in the IVIG-nonresponder group. KD patients show abnormal urinary findings such as proteinuria, hematuria and sterile pyuria, and severe cases may have interstitial nephritis, acute renal failure, etc., rarely. Sterile pyuria is caused less by urethritis than by renal parenchymal injury and inflammation in KD, and it is also closely associated with cytokines. KD causes also abnormalities in lipid metabolism due to the effects of cytokines such as TNF-α, IL-1 and IL-6. With the decrease of HDL, triglyceride increases. TNF-α and IL-1 decreases HDL by damaging the activity of lipoprotein lipase, and increases triglyceride through decreasing circulating lipoprotein and increasing hepatic lipid synthesis. In our study, HDL was significantly different between the two groups, but because the value of lipid profile is affected by diet it may have a limitation as a predictive marker of IVIG-responders and IVIG-nonresponders.

NT-proBNP, a widely used biomarker of cardiovascular disease, is cardiac hormone secreted by the ventricles in response to shear stress from the overload of body fluid and pressure. It is involved in diuresis, natriuresis, and arterial and venous dilatation and plays the role of regulating myocardial proliferation and hypertrophic response. NT-proBNP is a very important biomarker for the diagnosis, treatment and prognosis of heart failure in adults, and it is a predictor of cardiac functions in patients after cardiac infarction. In pediatric patients as well, NT-proBNP is a significant biomarker for heart failure, congenital heart disease with left-to-right shunt, cyanotic heart disease, right heart disease, secondary right heart disease induced by pulmonary hypertension and pulmonary regurgitation, and allograft disease after heart transplantation. Not as in other febrile illnesses, what is more, it increases at the acute stage of KD and decrease at the convalescent stage, so it is useful for diagnosis. Among cytokines, TNF-α and IL-1β accelerate the secretion of NT-proBNP, and secondarily the secretion of NT-proBNP is accelerated by subclinical myocarditis and ischemia.
in KD\(^6\). In this study, NT-proBNP was statistically significantly higher in the IVIG-nonresponder group. Because its variation is large according to age, however, NT-proBNP may be considered clinically but has a limitation in being used as a predictor\(^{22}\).

With excluding parameters which have problems in being used as a predictor, we could obtain the predictors of KD nonresponsive to IVIG using risk factors confirmed from our data and several factors suggested in previous studies. ALT≥84 IU/dL and total bilirubin≥0.9 mg/dL can be used as important independent risk factors for IVIG-resistant KD. These results imply that severe inflammation spread to the hepatic reticuloendothelial system by the impact of several cytokines and natural killer cells in the IVIG-nonresponder group.

Limitations of this study are that the number of IVIG-nonresponders was too small to represent the sample, and that the study was conducted retrospectively at two medical centers. In addition, echocardiography for diagnosing coronary artery lesions was performed by different examiners.

In conclusion, IVIG and high dose aspirin are established treatment methods of KD. There are still the controversial questions of what risk factors predict patients not responding to IVIG and what additional treatments should be applied to reduce coronary artery lesions. If a large-scale study is conducted with the whole population of KD pediatric patients, we may find the risk factors of KD not responding to IVIG. Then, we may be able to suggest new treatment guidelines different from existing treatment methods and to prevent coronary artery complications caused by KD.

References

1. Harnden A, Takahashi M, Burgner D. Kawasaki disease. BMJ 2009;338:b1514.
2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708–33.
3. Royle J, Burgner D, Curtis N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health 2005;41:87–93.
4. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010;8:197–203.
5. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004;163:285–91.
6. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606–12.
7. Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008;153:365–6.
8. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gammaglobulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131–7.
9. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237–40.
10. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117–21.
11. Do YS, Kim KW, Chun JK, Cha BH, Namgoong MK, Lee HY. Predicting factors for refractory Kawasaki disease. Korean Circ J 2010;40:239–42.
12. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr 2010;99:1578–81.
13. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006;21:778–81.
14. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007;22:987–91.
15. Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CC, et al. Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta 1997;260:15–26.
16. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Plasma inflammation in Kawasaki disease. Pediatr Nephrol 2006;21:987–91.
17. Yun SW, Lee HS, Kim DW, Rhee KW, Jung YS. Changes of lipid and lipoprotein compositions in Kawasaki disease and its impact on cardiac complications. Korean J Pediatr 2005;48:1370–7.
18. Davis GK, Bamforth F, Sarpal A, Dicke F, Rabi Y, Lyon ME. B-type natriuretic peptide in Kawasaki disease. Clin Biochem 2006;39:600–5.
19. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005;11(5 Suppl):S81–3.
20. Newton PJ, Bethivasav, Macdonald P. The role of B-type natriuretic peptide in heart failure management. Aust Crit Care 2009;22:117–23.
21. Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide measurement in cardiovascular disease. Heart Lung Circ 2005;14:78–84.
22. Nir A, Lindinger A, Rauh M, Bar-Oz B, Luer S, Schwachtgen L, et al. NT-ProB-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3–8.
23. Nasser N, Bar-Oz B, Nir A. Natriuretic peptides and heart disease in infants and children. J Pediatr 2005;147:248–53.
24. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005;11(5 Suppl):S76–80.
25. Dahdah N, Silkes A, Fournier A, Coutureau J, Delvin E, Saint-Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810–7.
26. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241–8.